日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Burden of long-term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT-O study

长期疾病负担及超重和肥胖人群的管理：来自 IMPACT-O 研究英国初级保健队列的数据

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.70345
Khunti, Kamlesh; Capehorn, Matt; Artime, Esther; von Arx, Lill-Brith; Davies, Alun L; Adam, Atif; Lampropoulou, Anastasia
肥胖
代谢
发表日期：2026
文献求助 收藏

Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective

替拉帕肽与利拉鲁肽联合饮食和运动治疗肥胖或超重患者的成本效益分析：英国视角

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03288-3
Capehorn, Matthew; Johansson, Erin; Davies, Alun; Evans, Jerome; Godbeer, Fiona; van Hest, Naomi; Cotterill, Georgina; Tolley, Keith
肥胖
代谢
发表日期：2025
文献求助 收藏

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

索玛鲁肽对高敏C反应蛋白的影响：SUSTAIN和PIONEER随机临床试验的探索性患者水平分析

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-022-01585-7
Mosenzon, Ofri; Capehorn, Matthew S; De Remigis, Alessandra; Rasmussen, Søren; Weimers, Petra; Rosenstock, Julio
发表日期：2022
文献求助 收藏

Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering Committee

英国医疗保健教育中肥胖症护理能力工作组的建议：指导委员会报告

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-022-02108-2
Capehorn, Matthew S; Hinchliffe, Nigel; Cook, Deborah; Hill, Andrew; O'Kane, Mary; Tahrani, Abd A; Vincent, Ann; Williams, Simon; Feenie, John
肥胖
代谢
发表日期：2022
文献求助 收藏

The Potential Role of Digital Health in Obesity Care

数字健康在肥胖症护理中的潜在作用

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-022-02265-4
Hinchliffe, Nigel; Capehorn, Matthew S; Bewick, Michael; Feenie, John
肥胖
代谢
发表日期：2022
文献求助 收藏

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

在英国，评估每周一次注射1毫克司美格鲁肽与25毫克恩格列净治疗2型糖尿病患者的成本效益

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-020-00989-6
Capehorn, Matthew; Hallén, Nino; Baker-Knight, James; Glah, Divina; Hunt, Barnaby
糖尿病
代谢
发表日期：2021
文献求助 收藏

Costs of the COVID-19 pandemic associated with obesity in Europe: A health-care cost model

欧洲与肥胖相关的 COVID-19 大流行成本：医疗保健成本模型

期刊:Clinical Obesity
影响因子:2.1
doi:10.1111/cob.12442
Czernichow, Sebastien; Bain, Stephen C; Capehorn, Matthew; Bøgelund, Mette; Madsen, Maria Elmegaard; Yssing, Cecilie; McMillan, Annabell Cajus; Cancino, Ana-Paula; Panton, Ulrik Haagen
肥胖
代谢
发表日期：2021
文献求助 收藏

Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials

基线特征和β细胞功能对每周一次皮下注射索玛鲁肽的疗效和安全性的影响：SUSTAIN 1-5试验的患者水平汇总分析

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.13896
Aroda, Vanita R; Capehorn, Matthew S; Chaykin, Louis; Frias, Juan P; Lausvig, Nanna L; Macura, Stanislava; Lüdemann, Jörg; Madsbad, Sten; Rosenstock, Julio; Tabak, Omur; Tadayon, Sayeh; Bain, Stephen C
细胞生物学
发表日期：2020
文献求助 收藏

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

每周一次司美格鲁肽与恩格列净联合二甲双胍治疗2型糖尿病的疗效比较：患者水平荟萃分析

期刊:Journal of Clinical Endocrinology & Metabolism
影响因子:5.1
doi:10.1210/clinem/dgaa577
Lingvay, Ildiko; Capehorn, Matthew S; Catarig, Andrei-Mircea; Johansen, Pierre; Lawson, Jack; Sandberg, Anna; Shaw, Robert; Paine, Abby
糖尿病
代谢
发表日期：2020
文献求助 收藏

Efficacy of an intermittent energy restriction diet in a primary care setting

间歇性能量限制饮食在基层医疗机构中的疗效

期刊:European Journal of Nutrition
影响因子:4.3
doi:10.1007/s00394-019-02098-y
Antoni, R; Johnston, K L; Steele, C; Carter, D; Robertson, M D; Capehorn, M S
发表日期：2020
文献求助 收藏